Prostate Cancer - Results from #23860

High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers - Abstract February 21, 2013

Targeted prostate biopsies for a histogram of the index lesion - Abstract February 21, 2013

GU Cancers Symposium 2013 - Real-world experience with sipuleucel-T in metastatic castration-resistant prostate cancer patients ≥ 80 years-old: Data from PROCEED - Session Highlights February 21, 2013

GU Cancers Symposium 2013 - Immune response to sipuleucel-T in patients with metastatic castrate-resistant prostate cancer (mCRPC): Phase 2 ProACT study, by Thomas A. Gardner, MD, et al. - Session Highlights February 20, 2013

GU Cancers Symposium 2013 - Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE) February 20, 2013

GU Cancers Symposium 2013 - A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer, by Eric J. Small, MD, et al. - Podcast February 20, 2013

GU Cancers Symposium 2013 - Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for localized prostate cancer, by Matthew R. Cooperberg, MD, MPH, et al. - Session Highlights and Podcast February 20, 2013

GU Cancers Symposium 2013 - Open-label, multicenter study of sipuleucel-T in metastatic castrate-resistant prostate cancer patients previously treated with sipuleucel-T: Evaluation of androgen-presenting cell activation, by L. Michael Glode, MD, et al. February 20, 2013

GU Cancers Symposium 2013 - Utilization of cancer detection by U.S. prostate biospies (2005-2011), by Carl A. Olsson, MD, et al. - Session Highlights and Podcast February 20, 2013

GU Cancers Symposium 2013 - The ERα agonist, GTx-758, decreases bone turnover markers in men with advanced prostate cancer, by Evan Y. Yu, MD, et al. - Poster February 20, 2013

GU Cancers Symposium 2013 - Advanced prostate cancer patients treated with GTx-758 have a significantly lower rate of hot flashes, by Evan Y. Yu, MD, et al. - Poster February 20, 2013

GU Cancers Symposium 2013 - ARN-509 in men with high-risk non-metastatic castration-resistant prostate cancer, by Matthew R. Smith, MD, PhD - Session Highlights February 19, 2013

GU Cancers Symposium 2013 - ARN-509 in men with high-risk non-metastatic castration-resistant prostate cancer, by Matthew R. Smith, MD, PhD, et al. - Slide Presentation February 19, 2013

GU Cancers Symposium 2013 - GTx-758, an ERα agonist, reduces serum free testosterone and serum PSA in men with advanced prostate cancer, by Evan Y. Yu, MD, et al. - Poster February 19, 2013

Elderly prostate cancer patients: Patient information and shared decision making - Abstract February 19, 2013

Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications - Abstract February 19, 2013

Combining prostrate-specific antigen and Gleason score increases the diagnostic power of endorectal coil magnetic resonance imaging in prostate cancer pathological stage - Abstract February 19, 2013

Hybrid registration of prostate and seminal vesicles for image guided radiation therapy - Abstract February 19, 2013

Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer - Abstract February 19, 2013

Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy - Abstract February 19, 2013

Page 1194 of 1439